Cellular sources of IL-23 and IL-17A driving skin inflammation in psoriasis remain unclear. Using high-dimensional unsupervised flow cytometry analysis, mononuclear phagocytes T cells were examined the same lesions patients before during guselkumab (IL-23p19 blocker) or secukinumab (IL-17A treatment. Among CD11c+HLA-DR+ phagocytes, CD64brightCD163−CD14brightCD1c−CD1a‒ inflammatory monocyte‒like...
